244 related articles for article (PubMed ID: 22571664)
1. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
2. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
3. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.
Shi J; Wei L
J Cardiovasc Pharmacol; 2013 Oct; 62(4):341-54. PubMed ID: 23921309
[TBL] [Abstract][Full Text] [Related]
4. Rho kinase (ROCK) inhibitors.
Liao JK; Seto M; Noma K
J Cardiovasc Pharmacol; 2007 Jul; 50(1):17-24. PubMed ID: 17666911
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological effects of RhoA and Rho-associated kinase on cardiovascular system.
Cai A; Li L; Zhou Y
J Hypertens; 2016 Jan; 34(1):3-10. PubMed ID: 26556565
[TBL] [Abstract][Full Text] [Related]
6. RhoA/Rho-Kinase in the Cardiovascular System.
Shimokawa H; Sunamura S; Satoh K
Circ Res; 2016 Jan; 118(2):352-66. PubMed ID: 26838319
[TBL] [Abstract][Full Text] [Related]
7. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Shimokawa H; Satoh K
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
[TBL] [Abstract][Full Text] [Related]
8. The role of the RhoA/rho-kinase pathway in pulmonary hypertension.
Nossaman BD; Kadowitz PJ
Curr Drug Discov Technol; 2009 Mar; 6(1):59-71. PubMed ID: 19275543
[TBL] [Abstract][Full Text] [Related]
9. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
10. Small guanine nucleotide-binding protein Rho and myocardial function.
Ren J; Fang CX
Acta Pharmacol Sin; 2005 Mar; 26(3):279-85. PubMed ID: 15715922
[TBL] [Abstract][Full Text] [Related]
11. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
Eisa-Beygi S; Wen XY
Antiviral Res; 2015 Feb; 114():53-6. PubMed ID: 25512227
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase: important new therapeutic target in cardiovascular diseases.
Satoh K; Fukumoto Y; Shimokawa H
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
[TBL] [Abstract][Full Text] [Related]
13. Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.
Soliman H; Gador A; Lu YH; Lin G; Bankar G; MacLeod KM
Am J Physiol Heart Circ Physiol; 2012 Oct; 303(8):H989-H1000. PubMed ID: 22865386
[TBL] [Abstract][Full Text] [Related]
14. Long-term diabetic complications may be ameliorated by targeting Rho kinase.
Zhou H; Li Y
Diabetes Metab Res Rev; 2011 May; 27(4):318-30. PubMed ID: 21309060
[TBL] [Abstract][Full Text] [Related]
15. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.
Zhou Q; Gensch C; Liao JK
Trends Pharmacol Sci; 2011 Mar; 32(3):167-73. PubMed ID: 21242007
[TBL] [Abstract][Full Text] [Related]
16. Raf-1/CK2 and RhoA/ROCK signaling promote TNF-α-mediated endothelial apoptosis via regulating vimentin cytoskeleton.
Yang L; Tang L; Dai F; Meng G; Yin R; Xu X; Yao W
Toxicology; 2017 Aug; 389():74-84. PubMed ID: 28743511
[TBL] [Abstract][Full Text] [Related]
17. Rho kinase as a therapeutic target in cardiovascular disease.
Surma M; Wei L; Shi J
Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
[TBL] [Abstract][Full Text] [Related]
18. High glucose activates Raw264.7 macrophages through RhoA kinase-mediated signaling pathway.
Cheng CI; Chen PH; Lin YC; Kao YH
Cell Signal; 2015 Feb; 27(2):283-92. PubMed ID: 25446262
[TBL] [Abstract][Full Text] [Related]
19. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
20. Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
Dong M; Yan BP; Yu CM
Cardiovasc Hematol Agents Med Chem; 2009 Oct; 7(4):322-30. PubMed ID: 19607644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
